Join Growin Stock Community!

Baxter international inc.BAX.US Overview

US StockHealthcare
(No presentation for BAX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BAX AI Insights

BAX Overall Performance

BAX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BAX Recent Performance

-3.34%

Baxter international inc.

0.05%

Avg of Sector

-0.31%

S&P500

BAX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BAX Key Information

BAX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BAX Profile

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Price of BAX

BAX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BAX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.86
PE Ratio (TTM)
-
Forward PE
7.62
PS Ratio (TTM)
0.93
PB Ratio
1.71
Price-to-FCF
31.36
METRIC
VALUE
vs. INDUSTRY
Gross Margin
30.05%
Net Margin
-8.51%
Revenue Growth (YoY)
-12.54%
Profit Growth (YoY)
-29.75%
3-Year Revenue Growth
-8.54%
3-Year Profit Growth
-26.67%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.86
PE Ratio (TTM)
-
Forward PE
7.62
PS Ratio (TTM)
0.93
PB Ratio
1.71
Price-to-FCF
31.36
Gross Margin
30.05%
Net Margin
-8.51%
Revenue Growth (YoY)
-12.54%
Profit Growth (YoY)
-29.75%
3-Year Revenue Growth
-8.54%
3-Year Profit Growth
-26.67%

  • When is BAX's latest earnings report released?

    The most recent financial report for Baxter international inc. (BAX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BAX's short-term business performance and financial health. For the latest updates on BAX's earnings releases, visit this page regularly.

  • What is the operating profit of BAX?

    According to the latest financial report, Baxter international inc. (BAX) reported an Operating Profit of -729M with an Operating Margin of -24.51% this period, representing a decline of 67.59% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BAX's revenue growth?

    In the latest financial report, Baxter international inc. (BAX) announced revenue of 2.97B, with a Year-Over-Year growth rate of 8.03%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BAX have?

    As of the end of the reporting period, Baxter international inc. (BAX) had total debt of 9.7B, with a debt ratio of 0.48. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BAX have?

    At the end of the period, Baxter international inc. (BAX) held Total Cash and Cash Equivalents of 1.97B, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BAX go with three margins increasing?

    In the latest report, Baxter international inc. (BAX) did not achieve the “three margins increasing” benchmark, with a gross margin of 19.4%%, operating margin of -24.51%%, and net margin of -37.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BAX's profit trajectory and future growth potential.

  • Is BAX's EPS continuing to grow?

    According to the past four quarterly reports, Baxter international inc. (BAX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BAX?

    Baxter international inc. (BAX)'s Free Cash Flow (FCF) for the period is 444M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 26.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BAX?

    The latest valuation data shows Baxter international inc. (BAX) has a Price-To-Earnings (PE) ratio of -10.06 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.